Eagle Health Investments LP lifted its position in Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) by 3.1% during the first quarter, HoldingsChannel.com reports. The fund owned 119,464 shares of the company’s stock after acquiring an additional 3,564 shares during the period. Revolution Medicines makes up 2.0% of Eagle Health Investments LP’s portfolio, making the stock its 18th largest position. Eagle Health Investments LP’s holdings in Revolution Medicines were worth $11,618,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in RVMD. Vanguard Group Inc. lifted its holdings in Revolution Medicines by 6.7% in the 4th quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company’s stock valued at $1,331,739,000 after purchasing an additional 1,056,792 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Revolution Medicines by 8.3% in the fourth quarter. Janus Henderson Group PLC now owns 12,303,502 shares of the company’s stock valued at $980,036,000 after buying an additional 947,448 shares during the last quarter. Nextech Invest Ltd. raised its position in shares of Revolution Medicines by 20.7% in the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after buying an additional 1,304,347 shares during the last quarter. Paradigm Biocapital Advisors LP lifted its stake in shares of Revolution Medicines by 6.8% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 6,644,403 shares of the company’s stock worth $529,227,000 after buying an additional 421,112 shares in the last quarter. Finally, Bellevue Group AG lifted its stake in shares of Revolution Medicines by 21.7% in the third quarter. Bellevue Group AG now owns 5,573,838 shares of the company’s stock worth $260,298,000 after buying an additional 994,538 shares in the last quarter. 94.34% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity at Revolution Medicines
In other news, CFO Jack Anders sold 20,000 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total transaction of $3,366,600.00. Following the completion of the transaction, the chief financial officer directly owned 123,269 shares in the company, valued at $20,749,870.77. This trade represents a 13.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Mark A. Goldsmith sold 10,020 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $156.12, for a total value of $1,564,322.40. Following the transaction, the insider owned 267,330 shares of the company’s stock, valued at approximately $41,735,559.60. This represents a 3.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 132,497 shares of company stock valued at $21,470,486 over the last ninety days. 7.60% of the stock is owned by insiders.
Analyst Ratings Changes
View Our Latest Report on RVMD
Revolution Medicines Price Performance
Revolution Medicines stock opened at $188.07 on Tuesday. The company’s 50 day simple moving average is $169.74 and its 200-day simple moving average is $132.87. The company has a debt-to-equity ratio of 0.19, a quick ratio of 6.80 and a current ratio of 6.80. Revolution Medicines, Inc. has a 1 year low of $34.00 and a 1 year high of $194.56. The company has a market capitalization of $39.98 billion, a price-to-earnings ratio of -26.60 and a beta of 1.37.
Revolution Medicines (NASDAQ:RVMD – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.46). During the same period in the previous year, the firm earned ($1.13) EPS. As a group, equities research analysts expect that Revolution Medicines, Inc. will post -7.91 earnings per share for the current year.
Revolution Medicines Profile
Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.
The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.
Read More
- Five stocks we like better than Revolution Medicines
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report).
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
